

SENTINEL ARTICLES IN GYNECOLOGIC CANCER

Ovary/Fallopian/Primary Peritoneal

Disclaimer: This list represents a collection of articles identified by members of SGO as important in the context of specific disease sites, it is not meant to serve as a specific tool of study for examinations and has not been approved by governing organizations in education

1. Duska LR, Garrett L, Henretta M, et al. When “never-events” occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. *Gynecol Oncol.* 2010;116(3):374–377.
<https://pubmed.ncbi.nlm.nih.gov/19922988/>
2. Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of LN metastasis in primary mucinous carcinoma of the ovary. *Obstet Gynecol.* 2010;116(2, pt. 1):269–273.
<https://pubmed.ncbi.nlm.nih.gov/20664385/>
3. Powless CA, Aletti GD, Bakkum-Gamez JN, et al. Risk factors for LN metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. *Gynecol Oncol.* 2011;122(3):536–540. <https://pubmed.ncbi.nlm.nih.gov/21636114/>
4. Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. *Gynecol Oncol.* 1999;72(3):278–287.
<https://pubmed.ncbi.nlm.nih.gov/10053096/>
5. Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. *J Natl Cancer Inst.* 2005;97(8):560–566. <https://pubmed.ncbi.nlm.nih.gov/15840878/>
6. Garcia-Soto AE, Boren T, Wingo SN, et al. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? *Am J Obstet Gynecol.* 2012;206(3):242.e1–242.e5.
<https://pubmed.ncbi.nlm.nih.gov/22055337/>

7. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. *Lancet*. 2001;357(9251):176–182.
<https://pubmed.ncbi.nlm.nih.gov/11213094/>
8. Van Le L. Stage IC ovarian cancer: the clinical significance of intraoperative rupture. *Obstet Gynecol*. 2009;113(1):4–5. <https://pubmed.ncbi.nlm.nih.gov/19104352/>
9. Greer BE, Bundy BN, Ozols RF, et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2005;99(1):71–79.
<https://pubmed.ncbi.nlm.nih.gov/16039699/>
10. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. *Cancer*. 2006;106(9):1933–1939. <https://pubmed.ncbi.nlm.nih.gov/16572412/>
11. Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. *Obstet Gynecol*. 2012;120(3):612–618. <https://pubmed.ncbi.nlm.nih.gov/22914471/>
12. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. MRC OV05; EORTC 55955 investigators. *Lancet*. 2010;376(9747):1155–1163. <https://pubmed.ncbi.nlm.nih.gov/20888993/>
13. Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. *J Natl Cancer Inst*. 2003;95(2):125–132. <https://pubmed.ncbi.nlm.nih.gov/12529345/>
14. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. *J Natl Cancer Inst*. 2003;95(2):113–125.
<https://pubmed.ncbi.nlm.nih.gov/12529344/>

15. Baptist Trimbos, Petra Timmers, Sergio Pecorelli, Corneel Coens, Koen Ven, Maria van der Burg, and Antonio Casado. Surgical Staging and Treatment of Early Ovarian Cancer: Long-term Analysis From a Randomized Trial PMID: PMC2911043 *J Natl Cancer Inst.* 2010 July 7; 102(13): 982–987.
<https://pubmed.ncbi.nlm.nih.gov/20445161/>
16. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. *Lancet.* 1998;352(9140): 1571–1576.
<https://pubmed.ncbi.nlm.nih.gov/9843101/>
17. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet.* 2003;361(9375):2099–2106.
<https://pubmed.ncbi.nlm.nih.gov/12826431/>
18. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup (GCIg). *J Clin Oncol.* 2009;27:1419–1425. <https://pubmed.ncbi.nlm.nih.gov/19224846/>
19. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med.* 2011;365(26):2484–2496. Erratum in: *N Engl J Med.* 2012;366(3):284.
<https://pubmed.ncbi.nlm.nih.gov/22204725/>
20. Hreshchyshyn MM, Park RC, Blessing JA, et al. The role of adjuvant therapy in stage I ovarian cancer. *Am J Obstet Gynecol.* 1980;138(2):139–145. <https://pubmed.ncbi.nlm.nih.gov/6252780/>
21. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med.* 1996;334(1):1–6. <https://pubmed.ncbi.nlm.nih.gov/7494563/>
22. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. *J Natl Cancer Inst.* 2000;92(9):699–708. <https://pubmed.ncbi.nlm.nih.gov/10793106/>

23. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol*. 2000;18(1):106–115.
<https://pubmed.ncbi.nlm.nih.gov/10623700/>
24. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2006;102(3):432–439. <https://pubmed.ncbi.nlm.nih.gov/16860852/>
25. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol*. 2003;21(17):3194–3200.
<https://pubmed.ncbi.nlm.nih.gov/12860964/>
26. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med*. 2011;365(26):2473–2483. <https://pubmed.ncbi.nlm.nih.gov/22204724/>
27. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. *J Natl Cancer Inst*. 2004;96(22):1682–1691. <https://pubmed.ncbi.nlm.nih.gov/15547181/>
28. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol*. 1995;13(7):1589–1599.
<https://pubmed.ncbi.nlm.nih.gov/7602348/>
29. Fruscio R, Garbi A, Parma G, et al. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. *J Natl Cancer Inst*. 2011;103(4):347–351.
<https://pubmed.ncbi.nlm.nih.gov/21217084/>
30. Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. *J Clin Oncol*. 1996;14(7):2113–2119. <https://pubmed.ncbi.nlm.nih.gov/8683244/>

31. Jakobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. *J Clin Oncol*. 1997;15(1):193–198. <https://pubmed.ncbi.nlm.nih.gov/8996142/>
32. Gore M, Mainwaring P, A'Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. *J Clin Oncol*. 1998;16(7):2426–2434. <https://pubmed.ncbi.nlm.nih.gov/9667260/>
33. Omura GA, Brady MF, Look KY, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. *J Clin Oncol*. 2003;21(15):2843–2848. <https://pubmed.ncbi.nlm.nih.gov/12807937/>
34. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. *J Clin Oncol*. 1994;12(12):2654–2666. <https://pubmed.ncbi.nlm.nih.gov/7989941/>
35. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet*. 2009;374(9698):1331–1338. <https://pubmed.ncbi.nlm.nih.gov/19767092/>
36. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. *J Clin Oncol*. 1994;12(9):1748–1753. <https://pubmed.ncbi.nlm.nih.gov/7916038/>
37. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. *N Engl J Med*. 1996;335(26):1950–1955. <https://pubmed.ncbi.nlm.nih.gov/8960474/>
38. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. *J Clin Oncol*. 2001;19(4):1001–1007. <https://pubmed.ncbi.nlm.nih.gov/11181662/>

39. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med*. 2006;354(1):34–43. <https://pubmed.ncbi.nlm.nih.gov/16394300/>
40. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2006;100(1):27–32. <https://pubmed.ncbi.nlm.nih.gov/16368440/>
41. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. *J Clin Oncol*. 2003;21(13):2460–2465. <https://pubmed.ncbi.nlm.nih.gov/12829663/>
42. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m²) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. *Gynecol Oncol*. 2009;114(2):195–198. <https://pubmed.ncbi.nlm.nih.gov/19447479/>
43. McMeekin DS, Tillmanns T, Chaudry T, et al. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. *Gynecol Oncol*. 2004;95(1):157–164. <https://pubmed.ncbi.nlm.nih.gov/15385126/>
44. Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel 3 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2011;122(1):89–94. <https://pubmed.ncbi.nlm.nih.gov/21529904/>
45. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol*. 2006;24(29):4699–4707. <https://pubmed.ncbi.nlm.nih.gov/16966687/>

46. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. *Gynecol Oncol*. 2004;95(1):1–8.
<https://pubmed.ncbi.nlm.nih.gov/15385103/>
47. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol*. 2012;30(17):2039–2045. <https://pubmed.ncbi.nlm.nih.gov/22529265/>
48. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. *J Clin Oncol*. 2010;28(20):3323–3329.
<https://pubmed.ncbi.nlm.nih.gov/20498395/>
49. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. *Ann Surg Oncol*. 2006;13(12):1702–1710. <https://pubmed.ncbi.nlm.nih.gov/17009163/>
50. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. *Int J Gynecol Cancer*. 2011;21(2):289–295. <https://pubmed.ncbi.nlm.nih.gov/21270612/>
51. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. *N Engl J Med*. 1995;332(10):629–634. <https://pubmed.ncbi.nlm.nih.gov/7845426/>
52. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. *N Engl J Med*. 2004;351(24):2489–2497. <https://pubmed.ncbi.nlm.nih.gov/15590951/>
53. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIc or IV ovarian cancer. *N Engl J Med*. 2010;363(10):943–953. <https://pubmed.ncbi.nlm.nih.gov/20818904/>

54. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol*. 2002;20(5):1248–1259. <https://pubmed.ncbi.nlm.nih.gov/11870167/>
55. Hamilton CA, Miller A, Miller C, et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2011;122(3):521–526. <https://pubmed.ncbi.nlm.nih.gov/21683993/>
56. Winter WE III, Kucera PR, Rodgers W, et al. Surgical staging in patients with ovarian tumors of low malignant potential. *Obstet Gynecol*. 2002;100:671–676. <https://pubmed.ncbi.nlm.nih.gov/12383532/>
57. Gershenson DM, Silva EG, Tortolero-Luna G, et al. Serous borderline tumors of the ovary with noninvasive peritoneal implants. *Cancer*. 1998;83(10):2157–2163. <https://pubmed.ncbi.nlm.nih.gov/9827720/>
58. Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. *Obstet Gynecol*. 2002;99(1):3–10. <https://pubmed.ncbi.nlm.nih.gov/11777502/>
59. Stewart SL, Wike JM, Foster SL, et al. The incidence of primary fallopian tube cancer in the United States. *Gynecol Oncol*. 2007;107(3):392–397. <https://pubmed.ncbi.nlm.nih.gov/17961642/>
60. Hu CY, Taymour ML, Hertig AT. Primary carcinoma of the fallopian tube. *Am J Obstet Gynaecol* 1950; 59:58–67. <https://pubmed.ncbi.nlm.nih.gov/15399626/>
61. Sedlis A. Carcinoma of the fallopian tube. *Surg Clin North Am* 1978; 58:121–129. <https://pubmed.ncbi.nlm.nih.gov/644422/>
62. Slayton RE, Park RC, Silverberg SG, et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group study (a final report). *Cancer*. 1985;56(2):243–248. <https://pubmed.ncbi.nlm.nih.gov/2988740/>
63. Williams SD, Blessing JA, Moore DH. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors: a trial of the Gynecologic Oncology Group. *Ann Intern Med*. 1989;111(1):22–27. <https://pubmed.ncbi.nlm.nih.gov/2472080/>

64. Li J, Yang W, Wu X. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. *Gynecol Oncol*. 2007;105(3):769–775.
<https://pubmed.ncbi.nlm.nih.gov/17459461/>
65. Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. *J Clin Oncol*. 1994;12(4):701–706. <https://pubmed.ncbi.nlm.nih.gov/7512129/>
66. Williams SD, Blessing JA, Hatch KD, et al. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. *J Clin Oncol*. 1991;9(11):1950–1955.
<https://pubmed.ncbi.nlm.nih.gov/1719142/>
67. Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. *Gynecol Oncol*. 2004;95(3):496–499. <https://pubmed.ncbi.nlm.nih.gov/15581952/>
68. Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? *Gynecol Oncol*. 2009;113(1):86–90.
<https://pubmed.ncbi.nlm.nih.gov/19162310/>
69. Wolf JK, Mullen J, Eifel PJ, Burke TW, Levenback C, Gershenson DM. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. *Gynecol Oncol* 1999;73(1):35–41.
<https://pubmed.ncbi.nlm.nih.gov/10094877/>
70. Homesley HD, Bundy BN, Hurteau JA, et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. *Gynecol Oncol*. 1999;72(2):131–137. <https://pubmed.ncbi.nlm.nih.gov/10021290/>
71. Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. *Gynecol Oncol*. 2011;123(3):610–614.
<https://pubmed.ncbi.nlm.nih.gov/21982047/>

72. Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade Lauraine, E., De Placido, S., ... Perrone, F. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol* 2014, 15(4), 396-405. <https://pubmed.ncbi.nlm.nih.gov/24582486/>
73. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., ... Matulonis, U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012, 366(15), 1382-1392. <https://pubmed.ncbi.nlm.nih.gov/22452356/>
74. Boulanger, J., Boursiquot, J. N., Cournoyer, G., Lemieux, J., Masse, M. S., Almanric, K., & Guay, M. P. (2014). Management of hypersensitivity to platinum- and taxane-based chemotherapy: ceppo review and clinical recommendations. *Curr Oncol* 2014, 21(4), e630-e641. <https://pubmed.ncbi.nlm.nih.gov/25089112/>
75. Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., ... Swart, A. M. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. *Lancet* 2010, 376(9747), 1155-1163. <https://pubmed.ncbi.nlm.nih.gov/20888993/>
76. Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., ... Mannel, R. S. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2017, 18(6), 779-791. <https://pubmed.ncbi.nlm.nih.gov/28438473/>
77. Moore, K., Colombo, N., Scambia, G., Kim, B., Oaknin, A., Friedlander, M., ... DiSilvestro, P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2018, 379(26), 2495-2505. [SOLO1 trial] <https://pubmed.ncbi.nlm.nih.gov/30345884/>
78. H. W. R., Hermans, R. H. M., ... Sonke, G. S. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. *N Engl J Med* 2018, 378(3), 230-240. <https://pubmed.ncbi.nlm.nih.gov/29342393/>
79. González Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., ... Monk, B. J. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2019, 381(25), 2391-2402. [PRIMA trial] <https://pubmed.ncbi.nlm.nih.gov/31562799/>

80. Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., ... Bookman, M. A. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. *N Engl J Med* 2019, 381(25), 2403-2415. [VELIA trial]
<https://pubmed.ncbi.nlm.nih.gov/31562800/>
81. Ray Coquard, I., Pautier, P., Pignata, S., Pérol, D., González Martín, A., Berger, R., ... Harter, P. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. *N Engl J Med* 2019, 381(25), 2416-2428. [PAOLA trial] <https://pubmed.ncbi.nlm.nih.gov/31851799/>